文献速递淋巴瘤

N6-甲基腺苷阅读蛋白IGF2BP2在外周T细胞淋巴瘤中的致癌与免疫逃逸作用

The N6-methyladenosine reader IGF2BP2 in T-cell lymphoma.
PubMed 文献 · Blood · 2026-01-01

该研究在外部队列及196例初诊外周T细胞淋巴瘤(PTCL)患者RNA测序数据中观察到IGF2BP2高表达,体外和体内实验表明IGF2BP2促进肿瘤生长并抑制CD8+ T细胞浸润。机制上IGF2BP2结合内体相关基因(RAB4、VPS35、RAB9、STAM)维持其稳定性,增强内吞活性,促进肿瘤增殖并抑制CD8+ T细胞毒性。靶向IGF2BP2的药物CWI1-2可抑制内吞和肿瘤生长。

要点

  • IGF2BP2在常见结节性PTCL亚型中高表达,并与患者RNA测序数据一致。
  • IGF2BP2通过稳定RAB4、VPS35、RAB9、STAM增强内吞,促进肿瘤生长并抑制CD8+ T细胞浸润。
  • CWI1-2靶向IGF2BP2可抑制内吞并在细胞系及PDX模型中抑制肿瘤生长。

核心结论

  • IGF2BP2是PTCL中临床相关的致癌驱动因子,通过内吞调控整合肿瘤生长与免疫逃逸。

研究设计与样本

  • 研究利用3个独立外部队列及196例初诊PTCL患者RNA测序数据,并结合体外、体内、PDX模型和患者样本共培养系统。

主要发现

  • IGF2BP2在常见结节性PTCL亚型中高表达,并在196例初诊PTCL的RNA测序数据集中得到验证。
  • IGF2BP2结合RAB4、VPS35、RAB9和STAM维持其稳定性,增强内吞活性,促进肿瘤细胞增殖并抑制CD8+ T细胞介导的细胞毒性。
  • CWI1-2靶向IGF2BP2可抑制内吞,并在细胞系和PDX模型中抑制肿瘤生长。

临床怎么用

  • IGF2BP2高表达可作为PTCL潜在致癌标志物,靶向IGF2BP2(如CWI1-2)可能同时抑制肿瘤生长和改善免疫微环境。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Peripheral T-cell lymphoma (PTCL) represents a highly heterogeneous and aggressive lymphoid neoplasm that lacks pathogenic biomarkers of RNA modification with therapeutic potential. IGF2BP2 is recognized as an N6-methyladenosine reader critically involved in oncogenesis. In this study, we observed consistently high expression of IGF2BP2 across common nodal PTCL subtypes in 3 independent external cohorts, which was further confirmed in our RNA-sequencing (RNA-seq) data set of 196 patients with newly diagnosed PTCL. Both in vitro and in vivo, IGF2BP2 promoted tumor cell growth and inhibited CD8+ T-cell infiltration within the tumor microenvironment. Mechanistically, IGF2BP2 bound to endosome-related genes (RAB4, VPS35, RAB9, and STAM) to maintain their stability, which resulted in enhanced endocytic activity and increased internalization of membrane proteins, and ultimately induced tumor cell proliferation and inhibition of CD8+ T-cell-mediated tumor cytotoxicity. The relationship between IGF2BP2 and endocytosis-associated genes was confirmed using RNA-seq data from patients with PTCL. IGF2BP2 as an upstream regulator of both tumor growth and immune suppression was further demonstrated in patient-derived xenograft models and a coculture system established using tumor samples from patients with PTCL and peripheral blood mononuclear cells. Notably, therapeutic targeting of IGF2BP2 with CWI1-2 suppressed endocytosis and impeded tumor growth in both cell lines and patient-derived xenograft models. Collectively, our findings highlight IGF2BP2 as a clinically relevant oncogenic driver in PTCL that integrates tumor-intrinsic growth signals with immune evasion through endocytosis-centered regulation, providing a novel therapeutic rationale for RNA modification-based strategies that concurrently target tumor cells and the tumor microenvironment.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Hu S, Qin Y, Yi HM, et al. The N6-methyladenosine reader IGF2BP2 in T-cell lymphoma. Blood. 2026. PMID: 42166364. doi:10.1182/blood.2026034186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。